Surface the same molecule clearing at 10x or 1000x the price into different destination markets. The geographic price-differentiation map for any API.
Linagliptin clears the India-out lanes across 15 destination markets in 2024 with a 794x price ratio between the cheapest and most expensive medians. Turkey clears at $2,200/kg median; Jordan goes higher at $2,089; Saudi Arabia sits at $2.77/kg on volume contract shipments. The same molecule, the same origin, the same year. The implication is direct: a buyer applying a single global list price to all 15 destinations is leaving multiples of margin on the high-paying lanes.
Type the molecule and origin. The AI agent pulls every destination market with declared clearance volume on the lane in the last 12 months.
Median USD/kg per destination is sorted, the max-to-min ratio is computed, and outlier rows below 5x global p10 are flagged separately.
Citation-anchored brief: the destination price ranking, the implied revenue uplift from shifting volume to high-paying lanes, and a flag where lanes have under 10 shipments (low confidence).
Same destination can carry multiple clearance bands when buyer types differ. PharmaDB surfaces each lane's percentile band so the arbitrage map is at the lane resolution, not a country average.
Lanes where the high-paying market clears at more than 10x the cheapest are flagged. These are the markets where a single global list price leaves multiples of margin on the table.
Destination-level medians aggregate across exporters. Identities are aggregated and anonymised; the disclaimer is respected at the query layer.
Trade aggregates flow in weekly. The arbitrage map moves with the market; the brief carries the exact computation timestamp.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve molecules · India-out 2024 · USD/kg destination medians, computed across 5+ markets.
Cross-market arbitrage is the price-differentiation map. PharmaDB pulls the destination-level medians for any molecule on the India-out (or any other origin) lanes, sorts them, and surfaces the ratio. The view is molecule_country_flow; the join is to the molecule catalog. Refresh cadence is weekly.
The observation that the same molecule, exported from the same origin in the same year, clears at very different median prices into different destination markets. The ratio of the highest to lowest median is the arbitrage signal. Large ratios mean a buyer applying a single list price is leaving margin on high-paying lanes.
Turkey and Korea typically clear smaller volumes at branded-equivalent prices; Saudi Arabia is one of the largest tender markets for linagliptin, where multi-exporter participation anchored to a published reference price compresses the lane median. The ratio is not a single buyer; it is a tender-market vs commercial-market structural difference.
Lanes with fewer than 5 declared shipments are excluded from the ratio compute. Rows with USD/kg below 0.01 are flagged as unit-mismatched and shown separately. The headline ratio uses cleaned medians only.
Trade values are USD at clearance, so FX is not the source of the spread. Intra-group transfer pricing can artificially compress one lane; PharmaDB surfaces a chip when a single counterparty dominates the lane's shipments, so the user can discount that data point.
Trade aggregates refresh weekly. The arbitrage map recomputes on every refresh; the catalog row carries the exact timestamp surfaced on the result page.
A benchmark gives the percentile band for one lane. The arbitrage map ranks all destinations for the same molecule. Both are derived from the same warehouse; the arbitrage map is the destination-comparison view.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.